Global End Stage Renal Disease (ESRD) Drug Market, By Type (Calcium Succinate, Mk-3866, Pacritinib, Sanguinate, Tesidolumab, Others), Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others), Indication (End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkalaemia), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
End Stage Renal Disease (ESRD) Drug Market Analysis and Size
According to the reports of the CDC, it is anticipated that more than 37 million people in the U.S. are suffering from CKD, however, globally, more than 500 million people are affected. An increasing number of patients suffering from kidney failure is estimated to drive the market. It has also been witnessed that people suffering from ESRD and diabetes are susceptible to COVID-19 complications compared to healthy individuals.
Data Bridge Market Research analyses a growth rate in the end stage renal disease (ESRD) drug market in the forecast period 2023-2030. The expected CAGR of the end stage renal disease (ESRD) drug market tends to be around 13.4% in the mentioned forecast period. The market value is USD 98.74 billion in 2022, and it would grow up to USD 270.01 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
End Stage Renal Disease (ESRD) Drug Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Calcium Succinate, Mk-3866, Pacritinib, Sanguinate, Tesidolumab, Others), Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others), Indication (End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkalaemia), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Kissei Pharmaceutical Co., Ltd (Japan)
|
|
Market Opportunities
|
|
Market Definition
End-stage kidney disease drugs are used widely to treat end-stage kidney disease also known as the late stage renal disease, which occurs when chronic kidney disease reaches an advanced state. In this stage, the kidneys can no longer work, as they should to meet the body's needs. It damages the nephron and the kidney cannot function to remove the waste product from the body. The disease can cause other severe problems such as kidney failure, hypertension, brain aneurysm, and chronic pain.
End Stage Renal Disease (ESRD) Drug Market Dynamics
Drivers
- Increased Incidence of Kidney Disease
The growing incidence of chronic end stage renal disease (ESRD) drug worldwide is majorly responsible for increasing market growth. According to the National Kidney Foundation records, approximately 10% of the global population is affected by chronic end-stage renal disease (ESRD) drug (CKD). According to WHO 2019, around 1.13 billion people globally have hypertension. In 2014–2016, diabetes and hypertension were majorly responsible for about 75% of kidney failure. Thus, it boosts market growth.
- Rising Demand For Blood Tests
Out of all the major tests, the main test for the diagnosis of end stage renal disease (ESRD) drug includes a blood test that helps understand the kidneys' functionality. It measures levels of a waste product known as creatinine in the blood. Additionally, the demand for these tests is expected to increase as the occurrence of CKD is high and increasing in many parts of the world. The global incidence of end-stage renal disease (ESRD) is high and rising at a huge rate. Therefore, it creates more opportunities for the market growth.
Opportunities
- Technological Advancements
There have been several advances regarding the diagnostic and treatment procedures that are increasing the market growth. For instance, FMCNA established the National Intensive Renal Care Reserve in April 2020, which comprised devices that can deliver IHD, CRRT, and SLED/PIRRT. Such conditions that cause reduced kidney function can lead to chronic kidney diseae (CKD), which may develop over time and lead to end-stage renal end stage renal disease (ESRD) where the kidney can no longer function independently. The first human clinical trials of blood purification technologies for designing Wearable Artificial Kidney 2.0 was approved by the U.S. FDA in February 2014. This innovation aims to obtain satisfactory and effective results from kidney failure patients. Hence, all these advancemnets are boosting the market growth.
Restraints/Challenges
- Side Effects of End stage renal disease (ESRD) Drugs
The major side effects that is related with these renal drugs could decrease the growth of the global renal drugs market during the forecast period. Effects such as fever, loss of appetite, and rashes, can hamper the market growth.
- High Cost of Treatment
The increased expenditure that is associated with these agents impedes the market growth. Treatments that include ACE inhibitors, diuretics, corticosteroids, and immunosuppressive therapy impede the growth of the market.
This end stage renal disease (ESRD) drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the end stage renal disease (ESRD) drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global End Stage Renal Disease (ESRD) Drug Market
The increasing cases of COVID-19 directly associate with the growth of kidney-related diseases. For instance, according to the article in 2021, titled "Acute Kidney Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital," around 4–37% of COVID-19 cases involve the kidneys, and acute end stage renal disease (ESRD) drugs have an occurrence of 50% among hospitalized COVID-19 patients. Therefore, it has been found that the COVID-19 is having a high impact on the kidney health of patients, which in turn, is projected to increase the burden of kidney disorders and boost the market growth.
Recent Developments
- In 2022, the Health Minister launched a Hemodialysis unit at New Souillac in the presence of the World Health Representative to celebrate world kidney day in Mauritius. It comprises 22 hemodialysis machines that can accommodate about 150 patients and aims at further decentralizing the treatment of patients suffering from kidney disease.
- In 2021, Baxter launched the Sharesource Analytics 1.0 Digital Health Module to increase the clinical management of home dialysis patients.
Global End Stage Renal Disease (ESRD) Drug Market Scope
The end stage renal disease (ESRD) drug market is segmented on the basis of type, product type, indication, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Calcium Succinate
- Mk-3866
- Pacritinib
- Sanguinate
- Tesidolumab
- Others
Product Type
- Calcimimetics
- Vitamin D
- Sterols
- Potassium Binders
- Calcium-Based Phosphate Binders
- Others
Indication
- End Stage Renal Disease (ESRD) Induced Hyperparathyroidism
- End Stage Renal Disease (ESRD) Induced Hyperphosphatemia
- End Stage Renal Disease (ESRD) Induced Hyperkalaemia
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
End Stage Renal Disease (ESRD) Drug Market Regional Analysis/Insights
The end stage renal disease (ESRD) drug market is analyzed and market size insights and trends are provided by type, product type, indication, distribution channel and end-user as referenced above.
The major countries covered in the end stage renal disease (ESRD) drug market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Europe has been witnessing the highest growth for the end stage renal disease (ESRD) drug market throughout the forecasted period due to the strong presence of highly developing economies such as India and China along with the huge development of the healthcare infrastructure.
North America dominates the market because of the increase in the incidence of renal disease, mainly amongst the elderly population and the easy availability of advanced features.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global End Stage Renal Disease (ESRD) Drug Market Share Analysis
The end stage renal disease (ESRD) drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to end stage renal disease (ESRD) drug market.
Key players operating in the end stage renal disease (ESRD) drug market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Fresenius SE & Co. KGaA (Germany)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Kissei Pharmaceutical Co., Ltd (Japan)
SKU-